EU Prescribing Patterns for Rituximab Biosimilars in Non-Hodgkin Lymphoma
European patients with non-Hodgkin lymphoma are more likely to be prescribed a rituximab biosimilar if they are in better overall health, have indolent histology, and have follicular lymphoma.
Source: OncLive